ClinicalTrials.gg

Program

CT-202

A development code.

Its studies are mostly in Triple Negative Breast Neoplasms, led by Context Therapeutics.

Furthest: phase 1, since Apr 16, 20261 company-led study, 1 open or runningNext primary completion: Jan 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Context Therapeutics11 open or runningphase 1since Apr 16, 2026Apr 16, 2026Jan 2030phase 1 · NCT07545122

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2026First study: phase 1 study in Triple Negative Breast NeoplasmsFirst studyNCT07545122 · 162 planned · Australia

Ahead

  1. Jan 2030Primary completion: phase 1 study in Triple Negative Breast NeoplasmsNCT07545122

TargetBeta

NECTIN4 →read by rule
“A Phase 1a/1b, First Time in Human Study of CT-202, A Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, and Urothelial Cancers”study text, by rule · the study

Other programs on NECTIN4

ProgramCompanyFurthest phaseStudies
enfortumab vedotinruleAstellas Pharmaphase 420
notiretatug rezetecanJiangsu HengRui Medicinephase 314
bulumtatug fuvedotinruleMabwell (Shanghai) Biosciencephase 313
Sutantatug EnvedotinruleCSPC Pharmaceutical Groupphase 36
zelenectide pevedotinrulebicycletx-limitedphase 25
Anti-nectin-4 Antibody-drug Conjugate MK-3120ruleMerckphase 25
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-nectin-4 Antibody-drug Conjugate IPH4502ruleinnate-pharmaphase 11
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rulerondo-therapeuticsphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07545122Triple Negative Breast Neoplasms · Australia1RecruitingJan 2030162

How it is read

Names in the registry

  • “CT-202”, 1 entry

Codes read as this program: CT202.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.